Neuroblastoma: Biology and molecular and chromosomal pathology

Lancet Oncology

Volumn 4, Issue 8, 2003, Pages 472-480

  Schwab, Manfred ^a   Westermann, Frank ^a   Hero, Barbara ^b   Berthold, Frank ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTROPHIN RECEPTOR; ONCOPROTEIN; PROTEIN MDM2; TUMOR MARKER;

AGE DISTRIBUTION; CANCER GROWTH; CANCER INCIDENCE; CANCER REGRESSION; CANCER STAGING; CHROMOSOME 11Q; CHROMOSOME 17Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL FEATURE; DISEASE CLASSIFICATION; GENE AMPLIFICATION; GENE DUPLICATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; MARKER GENE; MEDICAL RESEARCH; MOLECULAR GENETICS; NEUROBIOLOGY; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SOLID TUMOR;

EID: 0041475779     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01166-5     Document Type: Review

References (91)

1. Pritchard J, Hickman JA. Why does stage 4s neuroblastoma regress spontaneously? Lancet 1994; 344: 869-70.
2. Eklof O, Sandstedt B, Thonell S, Ahstrom L. Spontaneous regression of stage IV neuroblastoma. Acta Paediatr Scand 1983; 72: 473-76.
3. Fiorillo A, Migliorati R, Tamburrini O, et al. Prolonged survival of a patient with disseminated neuroblastoma. J Pediatr 1982; 101: 564-66.
4. Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59: 1261-77.
5. Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73: 405-16.
6. Schwab M, Shimada H, Joshi VV, Brodeur G. Neuroblastic tumours of adrenal gland and sympathetic nervous system. In: Kleihues P, Cavenee WK (Eds). Pathology and genetics: tumours of the nervous system. Lyon: IARC Press, 2000.
7. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983; 305: 245-48.
8. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998; 20: 473-79.
9. Godbout R, Squire J. Amplification of a DEAD box protein gene in retinoblastoma cell lines. Proc Natl Acad Sci USA 1993; 90: 7578-82.
10. Squire JA, Thorner PS, Weitzman S, et al. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene 1995; 10: 1417-22.
11. Amler LC, Schurmann J, Schwab M. The DDX1 gene maps within 400 kbp 5′ to MYCN and is frequently coamplified in human neuroblastoma. Genes Chromosomes Cancer 1996; 15: 134-37.
12. Wimmer K, Zhu XX, Lamb BJ, et al. Co-amplification of a novel gene, NAG, with the N-myc gene in neuroblastoma. Oncogene 1999; 18: 233-38.
13. Stanton LW, Schwab M, Bishop JM. Nucleotide sequence of the human N-myc gene. Proc Natl Acad Sci USA 1986; 83: 1772-76.
14. Ibson JM, Rabbitts PH. Sequence of a germ-line N-myc gene and amplification as a mechanism of activation. Oncogene 1988; 2: 399-402.
15. Schwab M, Ellison J, Busch M, et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984; 81: 4940-44.
16. Schwab M, Varmus HE, Bishop JM. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature 1985; 316: 160-62.
17. Schweigerer L, Breit S, Wenzel A, et al. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990; 50: 4411-16.
18. Lutz W, Schwab M. In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells. Oncogene 1997; 15: 303-15.
19. Ramsay G, Stanton L, Schwab M, Bishop JM. Human protooncogene N-myc encodes nuclear proteins that bind DNA. Mol Cell Biol 1986; 6: 4450-57.
20. Wenzel A, Cziepluch C, Hamann U, et al. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. Embo J 1991; 10: 3703-12.
21. Schwab M, Corvi R, Amler L. N-MYC Oncogene amplification: a consequence of genomic instability in human neuroblastoma. Neuroscientist 1995; 1: 277-85.
22. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17: 2264-79.
23. Schwab M. Oncogene amplification in neoplastic development and progression of human cancers. Crit Rev Oncog 1990; 2: 35-51.
24. Gaudray P, Szepetowski P, Escot C, et al. DNA amplification at 11q13 in human cancer: from complexity to perplexity. Mutat Res 1992; 276: 317-28.
25. Szepetowski P, Courseaux A, Carle GF, et al. Amplification of 11q13 DNA sequences in human breast cancer: D11S97 identifies a region tightly linked to BCL1 which can be amplified separately. Oncogene 1992; 7: 751-55.
26. Hellman A, Zlotorynski E, Scherer SW, et al. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 2002; 1: 89-97.
27. Amler LC, Schwab M. Amplified N-myc in human neuroblastoma cells is often arranged as clustered tandem repeats of differently recombined DNA. Mol Cell Biol 1989; 9: 4903-13.
28. Corvi R, Amler LC, Savelyeva L, et al. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells. Proc Natl Acad Sci USA 1994; 91: 5523-27.
29. Corvi R, Savelyeva L, Breit S, et al. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 1995; 10: 1081-86.
30. Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1997; 15: 1171-82.
31. Ikeda H, Iehara T, Tsuchida Y, et al. Experience with international neuroblastoma staging system and pathology classification. Br J Cancer 2002; 86: 1110-16.
32. Mora J, Gerald WL, Qin J, Cheung NK. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. Cancer 2002; 94: 2756-65.
33. Gehring M, Berthold F, Edler L, et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995; 55: 5366-69.
34. Corvi R, Savelyeva L, Schwab M. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells. Cancer Res 1995; 55: 3471-74.
35. Gratacos M, Nadal M, Martin-Santos R, et al. A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 2001; 106: 367-79.
36. Savelyeva L, Claas A, Matzner I, et al. Constitutional genomic instability with inversions, duplications, and amplifications in 9p23-24 in BRCA2 mutation carriers. Cancer Res 2001; 61: 5179-85.
37. Valent A, Le Roux G, Barrois M, et al. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification. J Pathol 2002; 198: 495-501.
38. Squire JA, Thorner P, Marrano P, et al. Identification of MYCN copy number heterogeneity by direct FISH analysis of neuroblastoma preparations. Mol Diagn 1996; 1: 281-89.
39. Caron H, van Sluis P, van Roy N, et al. Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 1994; 55: 341-47.
40. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells. Am J Hum Genet 1994; 55: 334-40.
41. Lastowska M, Cotterill S, Bown N, et al. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes Chromosomes Cancer 2002; 34: 428-36.
42. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 1999; 340: 1954-61.
43. Janoueix-Lerosey I, Penther D, Thioux M, et al. Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromosomes Cancer 2000; 28: 276-84.
44. Iehara T, Hamazaki M, Sawada T. Cytogenetic analysis of infantile neuroblastomas by comparative genomic hybridization. Cancer Lett 2002; 178: 83-89.
45. Brinkschmidt C, Christiansen H, Terpe HJ, et al. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome. Med Pediatr Oncol 2001; 36: 11-13.
46. Abel F, Ejeskar K, Kogner P, Martinsson T. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24. Br J Cancer 1999; 81: 1402-09.
47. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-30.
48. Meltzer SJ, O'Doherty SP, Frantz CN, et al. Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma. Br J Cancer 1996; 74: 1855-61.
49. Takita J, Hayashi Y, Takei K, et al. Allelic imbalance on chromosome 18 in neuroblastoma. Eur J Cancer 2000; 36: 508-13.
50. Hirai M, Yoshida S, Kashiwagi H, et al. 1q23 gain is associated with progressive neuroblastoma resistant to aggressive treatment. Genes Chromosomes Cancer 1999; 25: 261-69.
51. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999; 18: 4948-57.
52. Fong CT, White PS, Peterson K, et al. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992; 52: 1780-85.
53. Ejeskar K, Aburatani H, Abrahamsson J, et al. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer 1998; 77: 1787-91.
54. Weiss MJ, Guo C, Shusterman S, et al. Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Med Pediatr Oncol 2000; 35: 526-30.
55. Caron H, van Sluis P, Buschman R, et al. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum Genet 1996; 97: 834-37.
56. Mora J, Cheung NK, Chen L, et al. Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res 2001; 7: 1358-61.
57. Marshall B, Isidro G, Martins AG, Boavida MG. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Cancer Genet Cytogenet 1997; 96: 134-39.
58. Westermann F, Schwab M. Genetic parameters of neuroblastoma. Cancer Lett 2002; 184: 127-47.
59. Schwab M, Praml C, Amler LC. Genomic instability in 1p and human malignancies. Genes Chromosomes Cancer 1996; 16: 211-29.
60. Bauer A, Savelyeva L, Claas A, et al. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosomes Cancer 2001; 31: 228-39.
61. Cavenee WK, Dryja TP, Phillips RA, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 1983; 305: 779-84.
62. Takeda O, Homma C, Maseki N, et al. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma. Genes Chromosomes Cancer 1994; 10: 30-09.
63. Caron H, Spieker N, Godfried M, et al. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosomes Cancer 2001; 30: 168-74.
64. Mora J, Cheung NK, Kushner BH, et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2000; 2: 37-46.
65. Hiyama E, Hiyama K, Ohtsu K, et al. Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1. Med Pediatr Oncol 2001; 36: 67-74.
66. Spitz R, Hero B, Westermann F, et al. Fluorescence in situ hybridization analyses of chromosome band 1p36 in neuroblastoma detect two classes of alterations. Genes Chromosomes Cancer 2002; 34: 299-305.
67. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000; 18: 1888-99.
68. Rubie H, Delattre O, Hartmann O, et al. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Eur J Cancer 1997; 33: 1917-22.
69. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res 2003; 9: 52-58.
70. Luttikhuis ME, Powell JE, Rees SA, et al. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer 2001; 85: 531-37.
71. Plantaz D, Vandesompele J, Van Roy N, et al. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 2001; 91: 680-86.
72. Lastowska M, Cullinane C, Variend S, et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 2001; 19: 3080-90.
73. Snider WD. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 1994; 77: 627-38.
74. Klein R. Role of neurotrophins in mouse neuronal development. FASEB J. 1994; 8: 738-44.
75. Birren SJ, Lo L, Anderson GJ. Sympathetic neuroblasts undergo a developmental switch in trophic dependence. Development 1993; 119: 597-610.
76. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998; 11: 115-24.
77. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169: 107-14.
78. Nakagawara A, Arima M, Azar CG, et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-68.
79. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54.
80. Suzuki E, Bogenmann H, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85: 377-84.
81. Kogner P, Barbany G, Dominici C, et al. Coexpression of messenger RNA for IRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993; 53: 2044-50.
82. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759-67.
83. Yamashiro DJ, Liu XG, Lee CP, et al. Expression and function of Trk-C in favourable human neuroblastomas. Eur J Cancer 1997; 33: 2054-57.
84. Brodeur G, Ambros PF. Genetic and biological markers of prognosis in neuroblastoma. In: Brodeur G, Sawada T, Tsuchida Y, Voute P (Eds). Neuroblastoma. Amsterdam: Elsevier Science BV, 2000.
85. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 7: 673-79.
86. Berwanger B, Hartmann O, Bergmann E, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002; 2: 377-86.
87. Boon K, Caron HN, van Asperen R, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. Embo J 2001; 20: 1383-93.
88. Maris JM, Goo C, Blake D, et al. Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Med Pediatr Oncol 2001; 36: 32-36.
89. Ejeskar K, Sjoberg RM, Abel F, et al. Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol 2001; 36: 61-66.
90. Hogarty MD, Liu X, Guo C, et al. Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Med Pediatr Oncol 2000; 35: 512-15.
91. White PS, Thompson PM, Seifried BA, et al. Detailed molecular analysis of 1p36 in neuroblastoma. Med Pediatr Oncol 2001; 36: 37-41.